1. Introduction {#sec0005}
===============

The ramification of the mammalian vascular network occurs very early during embryogenesis in a complex and multifactorial process known as vasculogenesis ([@bib0540]). In humans, it starts approximately at day 18 after fertilization while in the mouse at embryonic day 7 from the extraembryonic mesoderm as formation of blood islands (yolk sac, connecting stalk and chorion) ([@bib0300]) and then proceeds within the splanchnic mesoderm by angioblast conversion into endothelial cells (ECs) ([@bib0215]).

From pre-existing vessels, the sprouting of capillaries leads to the formation of new microvasculature in a process known as angiogenesis that distributes to avascularized tissues bringing oxygen and nutrients ([@bib0060]; [@bib0420]). Recruitment of peri-endothelial vascular smooth muscle cells (VSMCs) from the ECs lining blood vessels consolidates the vasculogenetic process and provides a contractile protection layer to neo-formed vessels ([@bib0060]). The origin of EC and VSMC lineages has been shown to be highly heterogeneous and strictly depends on the organ in which the vascular web is developing.

2. The role of endothelium {#sec0010}
==========================

Angioblasts are the first endothelial progenitor cells (EPCs) within the blood islands of the yolk sac that reach the embryo to form the primitive vascular tree (Coffin et al., 1991, Hatzopoulos et al., 1998, [@bib0420]). Initially, homogeneous EPCs differentiate into specific phenotypes that are needed to support the diverse functions involved in sustaining blood flow, cell permeability and transport that each organ requires during development. Accordingly, ECs express specific molecular markers that identify and differentiate arterious, venous, and lymphatic endothelia, by the expression of specific gene signatures. ECs can be also recruited from bone marrow (BM) by action of vascular endothelial growth factor (VEGF) in order to induce neovascularization in physiological and pathological conditions ([@bib0020]; [@bib0040]). BM-ECs also play a role in tumor neoangiogenesis, although their contribution to cancer vessels can be variable, depending on cancer type or grade ([@bib0155]; [@bib0435]).

3. The role of VSMCs {#sec0015}
====================

If ECs originate from different regional sources and show high level of complexity, VSMCs are no exception. VSMC heterogeneity has been extensively described according to their proliferative or quiescent status that involve phenotypic switching and differences in cell morphology at confluence, production of growth factors or differential expression of cyclic nucleotide hydrolyzing enzymes ([@bib0150]; [@bib0375]). An additional level of heterogeneity comes from lineage tracing studies that identified distinct sources of VSMC progenitors colonizing different vessels, or even different areas of the same vessel ([@bib0310]).

VSMCs can be recruited to small vessels to form pericytes that regulate tissue microcirculation and vascular leakage ([@bib0015]; [@bib0130]). Pericyte origin can be the same as that of the arterial VSMCs, as demonstrated for the cephalic neural crest cells that colonize brain arteries and microvasculature ([@bib0165]), or for endocardial cells that colonize part of the coronary bed ([@bib0100]), however more studies are needed to understand where they originate from in other locations during development and in the adulthood. In the adult, arterial walls contain both proliferative and differentiated, contractile VSMCs within the medial layer and progenitor cells, mostly in the tunica adventitia, that contribute to form a stem cell reservoir ([@bib0330]). Several studies have shown that arterial VSMCs possess a different gene expression signature compared to the venous counterpart (reviewed in ([@bib0005]). VSMCs of arteries synthesize and secrete the majority of extracellular matrix (ECM) proteins and proteoglycans that confer elasticity and compliance to large arterious vessels and alteration of cell-ECM interaction leads to arterial stiffness during aging and disease \[for a review see ([@bib0290])\].

4. NO/cGMP/PDE5 pathway activity in EC and VSMC physiology {#sec0020}
==========================================================

Nitric oxide (NO) is a free radical gas, known to activate autocrine/paracrine pathways. Endothelial nitric oxide is a potent stimulus for angiogenesis ([@bib0515]) and its synthesis is controlled by VEGF that induces the specific endothelial NO synthase (eNOS) ([@bib0515]). As almost every cell, ECs are responsive to NO that activates soluble guanylyl cyclase (sGC) to produce cyclic guanosine monophosphate (cGMP), which in turn activates protein kinase G (PKG). NO produced by eNOS in endothelial cells acts paracrinally on neighbouring smooth muscle cells targeting sGC ([@bib0175]).

PKG acts on several downstream targets in VSMCs among which vasodilator-stimulated phosphoprotein (VASP), F-actin, extracellular signal-regulated kinase (ERK) 1/2 and p38 mitogen-activated protein kinase (MAPK), each contributing to NO angiogenic potential ([@bib0095]; [@bib0545]).

Type 5 phosphodiesterase (PDE5) belongs to a family of phosphodiesterases (PDEs) that hydrolyze cyclic nucleotides cAMP and/or cGMP second messengers ([@bib0035]). Among the family members, PDE5 is the predominant phosphodiesterase in vascular and trabecular smooth muscle cells that hydrolyzes specifically cGMP under basal condition (low calcium level), whereas PDE1, activated by Ca2+ / calmodulin, plays a pivotal role in high calcium conditions as, for example, during muscle contraction ([@bib0305]). We previously reported that PDE5 localizes in cytoplasmic vesicles and discrete cytoplasmic foci corresponding to centrosomes of several cell types ([@bib0150]). We also showed that PDE5 levels are inversely related to the mitotic activity of SMCs. Treatment of VSMCs with platelet-derived grow factor (PDGF), a potent mitogen for this cell type, downregulates PDE5 expression, an effect that is similar to that of human chorionic gonadotropin (hCG) on human myometrial cells ([@bib0070]; [@bib0150]).

5. PDE5 inhibitors {#sec0025}
==================

Serendipitously discovered more than 20 years ago with the aim to protect the damaged cardiac tissue by inhibiting the PDE5, sildenafil is the first and one of the most powerful PDE5 inhibitors (PDE5i) identified that showed penile erections as a common side effect \[see ([@bib0200]) and references therein\]. The cardioprotection was found relatively weak, but thanks to the specific high expression of PDE5 in the VSMCs of the penis, the drug was classified as the first oral treatment of erectile dysfunction ([@bib0220]). To date, four marketed PDE5i are available with identical pharmacodynamic properties, targeting the same enzyme, but with different specificities and pharmacokinetic characteristics ([@bib0255]). Avanafil is the PDE5i with the highest specificity for PDE5 ([@bib0530]). The lowest cross-reaction with the other PDEs account for its excellent tolerability profile ([@bib0120]). Vardenafil has a pharmacokinetic profile similar to sildenafil, but with a lower IC~50~, indicating how much of a drug is needed to inhibit PDE5 activity by 50 % ([@bib0410]). Tadalafil, which, at low daily dose, is also approved for the treatment of urinary lower tract symptoms ([@bib0225]), has the worst safety profile for the cross reaction with type 11 muscular PDE ([@bib0045]) producing severe back pain and myalgia in 2--3 % of patients treated. However, this drug shows the longest half-life (around 17 h, *vs* the average 4--5 of the others), a merit in absence of side effects, but a risk when adverse events are present.

The vascular activity of each PDE5i has been demonstrated to be peculiar. This might be linked to the stereochemical characteristics of the binding to the enzymatic substrate or possible cross-reaction with other substrates. In fact, 10 mg vardenafil daily did not alter endothelial function or arterial stiffness ([@bib0335]) and the same drug at a 20 mg regimen, as well 60 mg of tadalafil (a dose trice of the maximal for the on demand use and 12 times of that prescribed for the daily use) did not impact on arterial oxygenation in patients with pulmonary arterial hypertension (PAH), a severe vascular disease leading to a progressive increase in pulmonary vascular resistance ([@bib0195]). On the contrary, this specific effect, comparable to that of NO, was only seen with 50 mg of sildenafil ([@bib0285]). For this reason, sildenafil is approved, as for NO and tadalafil (at 40 mg/day, twice the maximal dose for ED), for the use in PAH. The specific ability in targeting the vascular performance was further demonstrated with penile dynamic Color Doppler Ultrasound (CDU), which found that only sildenafil, and not tadalafil nor vardenafil, was able to improve the hemodynamics of the penis of impotent patients ([@bib0250]). Sildenafil cross specificity to other PDEs may potentially account for the differential effects on vasodilation of this drug compared to vardenafil or tadalafil. While sildenafil shows a lower, albeit high, selectivity ratio for PDE1 with respect to vardenafil (40 *vs* 140, respectively), tadalafil is highly selective with respect to PDE1, while selectivity ratio with other PDEs is more than 1000 ([@bib0440]).

6. Role of PDE5 in VSMC and EC aging and disease: lessons from PDE5i {#sec0030}
====================================================================

Vascular aging is a degenerative process that affects the arterial walls representing the condition that precedes the onset of vascular disease, starting with the chronic inflammation of the intima-media unit, when dysmetabolic cues alter the local homeostasis. Modifications of the vascular tunica involve phenotypic changes of VSMCs, including cell death, calcification and mechano-sensing ability, contractile or proliferative switch, that in turn affect EC fitness leading to thickening and stiffening of the vascular wall ([@bib0295]).

Despite VSMC heterogeneity during development, PDE5 is highly expressed in VSMCs from almost every organ and is one of the most abundant cGMP-PDEs present in arterial SMCs together with PDE1A, 1B, and 1C, PDE3A and 3B ([@bib0320]). Three PDE5 isoforms have been identified in humans, including PDE5A1, PDE5A2, and PDE5A3 that differ in their respective 5′ terminus mRNAs originating from three alternative first exons in the pre-mRNA ([@bib0050]; [@bib0275]; [@bib0315]). The three isoforms, that show differential amino acid lengths, are all expressed in aortic VSMCs ([@bib0085]), possess similar cGMP catalytic activity and are sensitive to PDE5 specific inhibitors (see below) ([@bib0315]).

VSMC contractility is tightly regulated by NO/cGMP/PDE5 signalling, and dysregulation of this pathway can modify the vascular biology determining hypertension and/or age-related modification of vascular system ([@bib0340]) ([@bib0160]). In particular, age-related reduction of NO bioavailability is responsible for reduction in endothelium-dependent dilation, enhanced vasoconstriction, and dysregulation of tissue perfusion \[([@bib0510]) and references therein\]. In agreement, it has been shown that PDE5 and PDE1 mRNA levels and activity are elevated in senescent human VSMCs ([@bib0025]) and that such alterations can modify the vascular tone and contribute to the development of hypertension ([@bib0490]) implying that PDE5i might indeed improve VSMC tone regulation.

The majority of PDE5 studies on vascular aging and disease have been based on acute or chronic PDE5i administration to block PDE5 activity, assuming that this condition might equal PDE5 absence, since, to date, no animal models for *PDE5* deletion have been reported. Thus, other non-enzymatic actions or cross-reactions with additional substrates can not be excluded.

In this section, we reported PDE5 expression and/or enzymatic activity inhibition data studied in the different anatomical regions involving effects on VSMC and EC vascular compartments.

6.1. Aorta {#sec0035}
----------

PDE5 is the most expressed cGMP-PDE in the human aorta ([@bib0085]). Its expression is activated in the muscular layer early during embryogenesis. In 7 weeks old human embryo, as well as in E12 mouse embryos, PDE5 expression is initially found in the ventral mesenchymal area of the thoraco-abdominal segment that corresponds to the localization site of migratory VSMCs from somites in the chick dorsal aorta ([@bib0245]). We recently found that PDE5 isoforms A1 and A3 are both up-regulated by Notch3 in VSMCs *in vitro*, while all the three isoforms are strongly downregulated in thoracic aortic aneurysms (TAAs) ([@bib0085]). In line with our reports, three independent case reports of patients experiencing aortic aneurysm dissection following the abuse of sildenafil have been described ([@bib0170]; [@bib0360]; [@bib0500]).

6.2. Heart {#sec0040}
----------

PDE5 expression in the heart is quite controversial. While positivity to anti-PDE5 antibodies has been reported in coronary VSMCs ([@bib0110]; [@bib0465]), healthy myocardium does not seem to express high levels of the enzyme ([@bib0135]). A consistent upregulation of PDE5 has been, however, detected in congestive heart failure and right ventricular hypertrophy ([@bib0325]; [@bib0405]; [@bib0465]). In these conditions, angiotensin II stimulation of VSMCs determines the induction of PDE5 that, in turn, reduces cGMP/PKG signalling increasing the angiotensin II response ([@bib0270]). This loop can exacerbate hypertension and vascular proliferation in diseases involving renin/angiotensin stimulations. Sildenafil treatment prevents ventricular hypertrophy induced by transverse aortic ligation ([@bib0495]) and protects against ischemia-reperfusion injury. Indeed, Ockaili et al. demonstrated that infusion of sildenafil decreases the infarct size in a rabbit model ([@bib0365]). A recent study on a large Swedish cohort demonstrated that treatment for erectile dysfunction (ED) after a first myocardial infarct was associated with a reduced mortality and heart failure hospitalisation. Only patients treated with PDE5i had a reduced risk, which appeared to be dose-dependent, strongly favouring for a role of PDE5i in the relaxation of coronary SMC tone ([@bib0010]). Chronic use of sildenafil improves diabetic cardiomyopathy *via* an anti-remodelling effect, resulting in improved cardiac kinetics and circulating markers ([@bib0210]). PDE5i-dependent heart protection operated by tadalafil has been shown to be achieved through PGK-dependent hydrogen sulfide (H~2~S) intracellular signaling, which contributes to the opening of mitochondrial ATP-sensitive potassium channels and cell homeostasis maintenance ([@bib0450]). Moreover, inhibition of PDE5 has been shown to enhance ischemia-induced angiogenesis by mobilizing EPCs through a PKG-dependent HIF-1/VEGF pathway ([@bib0445]). In this scenario, it is conceivable to hypothesize future cardiac indications, albeit still debated ([@bib0115]). All these studies and the large bibliography on the beneficial effects of PDE5i on heart vascular function definitively prove that PDE5i do not show cardiovascular life-threatening adverse effects even if their synergistic interaction with NO-donors, such as nitrates frequently used for angina, should be avoided due to low blood pressure or syncope as side effects.

6.3. Dermis {#sec0045}
-----------

Vasomotor dysfunction of the cutaneous surface is a wide-spread disorder in older populations. It has been shown that PDE5 plays an important role in the regulation of capillary blood flow of extremities as demonstrated by successful PDE5i treatment of patients with therapy-resistant Raynaud's phenomenon ([@bib0190];). This condition is caused by episodic vasospasm and ischaemia of the extremities in response to cold temperatures or to emotional stress and can affect individuals at any age. In elderly patients, Raynaud's phenomenon is often a secondary event that masks a secondary disease, such as occlusive arterial, rheumatologic or haematologic diseases ([@bib0230]). Velocity of capillary blood flow, severely impaired in these patients, was able to increase up to \>400 % in sildenafil groups compared to placebo treated patients ([@bib0190]). PDE5 has also been shown to be expressed in the dermal compartment of mouse hair follicles, and *in vitro* treatment of dermal papillae with sildenafil induces VEGF and platelet derived growth factor A (PDGFA) secretion, increased dermal proliferation and neoangiogenesis ([@bib0105]), although studies in humans have not proved conclusive evidences ([@bib0460]).

6.4. Kidney {#sec0050}
-----------

PDE5 plays a pivotal role in the vascular dysfunction that characterizes the renovascular hypertension; indeed, sildenafil, the most frequently used treatment for impotence in renal failure ([@bib0520]), is able to restore the depressed baroreflex control in a rat model of renovascular hypertension ([@bib0075]). Although within the kidney parenchyma PDE5 shows a vascular expression only, studies have also demonstrated the beneficial effects of sildenafil treatment on renal cell apoptosis, oxidative stress and mesangial matrix deposition in chronic kidney disease and in diabetic mouse models as a result of renal microcirculation improvement ([@bib0260]; [@bib0400]; [@bib0425]).

6.5. Female genital apparatus and placental annexes {#sec0055}
---------------------------------------------------

As mentioned above, PDE5 is expressed in myometrium and in myometrial arteries and its levels are down-regulated by hCG *in vitro* ([@bib0030]). Its inhibition by sildenafil improves embryo implantation and pregnancy rates in a cohort of *in vitro* fertilization (IVF) low success patients ([@bib0480]), suggesting that PDE5 inhibition by hCG supports embryo implantation and early pregnancy. PDE5 immunoreactivity was also detected in VSMCs of the pseudocavernous tissue of the vaginal wall and in clitoral corpora cavernosa (D\'Amati et al., 2002; [@bib0385]), however it is not clear if it might play a role in female sexual dysfunction (FSD) and clinical trials on the use of PDE5i to treat FSD need further studies.

PDE5 is also highly expressed in umbilical arteries and counteracts fetal umbilical artery relaxation ([@bib0455]), suggesting a role in pregnancy-induced hypertension and preeclampsia. In agreement with this observation, a recent metanalysis quoted a large amount of animal and human studies that highlighted the beneficial effects of sildenafil on fetal growth restriction (FGR) due to placental insufficiency ([@bib0380]). More recent results obtained from the clinical trial STRIDER and from a randomised controlled trial ([@bib0470]), however, showed no such effect and no indications of efficacy.

6.6. Male genital apparatus {#sec0060}
---------------------------

PDE5 is abundantly expressed in the male genital apparatus; however, it is its localization in VSCMs of penile corpora cavernosa that made PDE5i discovery one of the most important revolutions of the last century. Such localization is conserved along the phylogenetic tree in low mammals at least down to snakes ([@bib0055]). Interestingly, PDE5 deregulation causes priapism in eNOS1-3 KO mice ([@bib0090]) indicating that PDE5 is a key player of erection control in different species that evolved with or without the *os penis*, or baculum ([@bib0080]).

Indeed, PDE5 expression is ontogenetically regulated and androgen-dependent in rats, with the highest levels of mRNA and protein expression in adult corpus cavernosum-derived SMCs (CC-SMCs) ([@bib0065]; [@bib0350]). PDGF induces proliferation of CC-SMCs and down-regulates PDE5 expression suggesting, as demonstrated for myometrial cells, that PDE5 marks the contractile phenotype of SMCs. Hyperoxia conditions positively control *PDE5* gene expression while, as expected, hypoxia down-regulates it. In agreement with these results we found that *Hif1α* overexpression *in vitro* down-regulated PDE5 protein levels and identified *in silico* two canonical Hif Responsive Elements (HREs) within the first and the second PDE5 promoter (unpublished results).

A beneficial effect on steroidogenesis and age-related regressive changes in the rat testis has been reported when elderly animals were chronically treated with PDE5i, although the target cells of PDE5 inhibition have not been identified ([@bib0485]).

6.7. Lung {#sec0065}
---------

While PDE3, PDE4 and PDE5 are the most expressed PDEs in bronchial/lung parenchyma, the most expressed PDE in fetal and postnatal lung arteries is PDE5 ([@bib0235]). Its expression, as well as its enzymatic activity, is strongly up-regulated by hyperoxia in *in vitro* cultured pulmonary fetal VSMCs and *in vivo* ([@bib0180]), playing a pivotal role in PAH. Indeed, persistent PAH of the newborn, a life-threatening condition, has been shown to be linked to PDE5 overexpression and overactivation ([@bib0180]), and several studies have shown that sildenafil mediated inhibition of PDE5 reduces pulmonary vascular resistance and vessels remodelling in PAH ([@bib0415]; [@bib0535]). The reduction of pulmonary vascular resistance and pressure after selective PDE5 inhibition are also associated with blood decrease of Endothelin-1 (ET-1) and attenuation of lung vessel hypoxia-induced inflammatory cytokine expression ([@bib0430]) ([@bib0505]). Recent clinical trials have succeeded in demonstrating the efficacy of sildenafil alone or in combination with ET-1 receptor antagonists to improve physical performances of patients affected by pulmonary hypertension alone or complicated by collagenopathies (SUPER-1 and COMPASS-2, respectively ([@bib0265]; [@bib0280])). Covid-19 viral lung infection, the pandemia that is currently causing thousands of victims for respiratory insufficiency, has been hypothesized to affect not only the alveolar compartment but also the pulmonary microvasculature. Given the efficacy of NO on reducing PAH, a clinical trial has now opened in USA to test the effects of NO inhalation on Covid-19 dependent acute respiratory distress syndrome (ARDS). Theoretically, by reducing the pulmonary arterial pressure NO will improve oxygen saturation and reduce the burden on the right ventricle. If NO inhalation will prove to be helpful, also PDE5i administration will be definitely beneficial to treat ARDS.

6.8. Blood {#sec0070}
----------

PDE5 expression in blood cells is confined to megakaryocytes and platelets. We and others have demonstrated that PDE5 is expressed both in fetal and postnatal platelet precursors and in terminally differentiated elements ([@bib0085]; [@bib0355]). Physiologically, PDE5 activity blunts the NO/cGMP/PKG activated pathway within a short period of time contributing to the control of platelet secretion and aggregation. Two other PDE isoenzymes, PDE2 and PDE3, with activity for both cAMP and cGMP are found in platelets ([@bib0240]), explaining why PDE5i alone do not show anti-coagulant side effects ([Fig. 1](#fig0005){ref-type="fig"} ).Fig. 1Schematic representation of NO/PDE5/PKG pathway in smooth muscle cells.NO released from endothelial cells activates soluble guanylate cyclase that produces cGMP from GTP. cGMP activates PKG that phosphorylates several substrates thus inhibiting smooth muscle contraction and promoting angiogenesis. PDE5 reverses this condition by hydrolizing cGMP to GMP while PDE5i (sildenafil, vardenafil, tadalafil, avanafil) all promote smooth muscle relaxation by inhibiting cGMP accumulation.Fig. 1

6.9. Brain {#sec0075}
----------

A role of PDE5 together with PDE1 has been highlighted in age-dependent cerebral vasculature alterations. Indeed, in a mouse model of age-dependent vascular dysfunctions, the inhibition of both PDE5 and 1 restored the vascular functions ([@bib0025]; [@bib0370]; [@bib0395]). Moreover, in a rat model of cerebral ischemia, sildenafil treatment improved angiogenesis and synaptogenesis around the ischemic boundary regions ([@bib0550]).

Since PDE5 was detected in cerebral and meningeal arteries both in humans and rodents ([@bib0395]), its involvement was analysed also in cerebral small vessel disease (SVD), a pathology that affects up to 70 % of older adults and that represents the most common cause of vascular cognitive impairment. Hypoperfusion due to SVD causes severe changes in subcortical areas that represent the first symptoms in Alzheimer's disease. By improving cerebral blood flow, hemodynamic function and oxygen metabolism, sildenafil was shown to impact on Alzheimer's disease ([@bib0475]). A phase 2 trial (named PASTIS) examining whether tadalafil can increase blood flow to the deep vessels within the brain, is near to closing stage and will clarify this important issue ([@bib0390]).

A summary of PDE5i on label and off label uses in vasculopathy is reported in [Fig. 2](#fig0010){ref-type="fig"} .Fig. 2PDE5i use in pathologies linked to vascular defects. On label refers to approved uses while off label refers to unapproved uses of PDE5i for the indications reported.Fig. 2

7. PDE5 and ECs {#sec0080}
===============

PDE5 is expressed in VSMCs but not or at least not at immunodetectable levels in ECs, however its inhibition exerts important effects on endothelium. When querying for PDE5/PDE5i and endothelial cells in Medline databases, an amount of reports identifies endothelium-dependent vasodilation as the beneficial effect of PDE5 inhibition on ECs. Although NO and PDE5i-mediated cGMP increase induces relaxation of VSMCs, an event that enhances O2 tension at endothelial level, few data are present in literature that identify molecular targets specific of ECs that are influenced by VSMC relaxation. In particular, it has been shown that PDE5 inhibition promotes the recruitment of EPCs, which consistently contribute to neoangiogenesis and vascular repair ([@bib0145]) ([@bib0185]), the decrease of ET-1 blood levels and of hypoxia-induced inflammatory cytokines such as (Intercellular Adhesion Molecule 1) ICAM-1, (Vascular Cell Adhesion Protein 1) VCAM-1, C-reactive protein (CRP) and Interleukin (IL)-6 ([@bib0525]). In line with this observation, we previously reported that blood level of CXCL10 and CXCL8 chemokines released by inflammation-activated human cardiomyocytes and endothelial cells, respectively, significantly decreased after sildenafil treatment in diabetic patients at the onset of cardiomyopathy ([@bib0140]; [@bib0205]) ([@bib0345]).

A summary of PDE5 expression in VSMC and EC vascular compartments is reported in [Table 1](#tbl0005){ref-type="table"} .Table 1PDE5 localization and effects of its activity or inhibition.Table 1PDE5 LocalizationEffectRef.Human myometrial cells, C2C12 myoblasts and rat corpora cavernosa cellsPDE5 expression is associated to quiescent, contractile SMCs and its levels are down regulated when VSMCs resume proliferation, suggesting that PDE5 is a marker of the contractile phenotype[@bib0150]Arterial SMCsDevelopmental increase in PDE5 may enable the ductus to constrict and remodel itself more efficiently after birth[@bib0320]Aortic VSMCsPDE5 isoforms A1 and A3 are both up-regulated by Notch3 in VSMCs *in vitro*, while all the three isoforms are strongly downregulated in thoracic aortic aneurysms[@bib0085]Senescent human VSMCsHigh levels of PDE5 cause vasoconstriction response that alters the vascular tone and contributes to the development of hypertension[@bib0025]; [@bib0025]; [@bib0490]Coronary VSMCsUpregulated myocardial PDE5 expression may contribute to the progression of heart failure[@bib0110]; [@bib0465]Myometrium and myometrial arteriesPDE5 marks the contractile phenotype of VSMCs[@bib0030]VSMCs of pseudocavernous tissue of vaginal wall and clitoral corpora cavernosaPDE5 might play a possible role in female sexual dysfunction[@bib0125]; [@bib0385]Umbilical arteriesPDE5 is highly expressed in umbilical arteries and counteracts fetal umbilical artery relaxation[@bib0455]VSMCs of penile corpora cavernosaPDE5 marks the contractile phenotype of SMCs[@bib0065]; [@bib0350]Pulmonary arteriesPDE5 inhibition reduces pulmonary vascular resistance and vessel remodelling[@bib0235]Cerebral and meningeal arteriesPDE5 inhibition improves cerebral blood flow, hemodynamic function and oxygen metabolism[@bib0395]

8. Concluding remarks {#sec0085}
=====================

This review has focused on the role of PDE5 on vascular development, aging and disease reporting on data obtained using specific PDE5 inhibitors. From all the results reviewed it emerges that PDE5 expression marks the contractile phenotype of VSMCs, that its "correct expression" correlates to the VSMC fitness and that its overactivity/overexpression is deleterious for the vascular health of almost all the organs of an individual. Although the huge amount of functional data present in the literature are based on results obtained by inhibition of PDE5, to date no results have been reported on the impact of PDE5 deletion on these processes, since no PDE5 knockout mouse models have been described yet. In particular it is not known if PDE5 absence might be compatible with correct embryonic or postnatal development and if other functions, apart from the enzymatic one, are attributable to this specific phosphodiesterase. Thus, further work is needed to clarify how PDE5 correct expression and function impact on this important issue.
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